| Literature DB >> 24391538 |
Anika Saul1, Ralf Hausmann2, Achim Kless3, Annette Nicke1.
Abstract
Transcripts and/or proteins of P2X receptor (P2XR) subunits have been found in virtually all mammalian tissues. Generally more than one of the seven known P2X subunits have been identified in a given cell type. Six of the seven cloned P2X subunits can efficiently form functional homotrimeric ion channels in recombinant expression systems. This is in contrast to other ligand-gated ion channel families, such as the Cys-loop or glutamate receptors, where homomeric assemblies seem to represent the exception rather than the rule. P2XR mediated responses recorded from native tissues rarely match exactly the biophysical and pharmacological properties of heterologously expressed homomeric P2XRs. Heterotrimerization of P2X subunits is likely to account for this observed diversity. While the existence of heterotrimeric P2X2/3Rs and their role in physiological processes is well established, the composition of most other P2XR heteromers and/or the interplay between distinct trimeric receptor complexes in native tissues is not clear. After a description of P2XR assembly and the structure of the intersubunit ATP-binding site, this review summarizes the distribution of P2XR subunits in selected mammalian cell types and the biochemically and/or functionally characterized heteromeric P2XRs that have been observed upon heterologous co-expression of P2XR subunits. We further provide examples where the postulated heteromeric P2XRs have been suggested to occur in native tissues and an overview of the currently available pharmacological tools that have been used to discriminate between homo- and heteromeric P2XRs.Entities:
Keywords: P2XR; clustering; heteromer; homomer; ligand binding site; subunit interface
Year: 2013 PMID: 24391538 PMCID: PMC3866589 DOI: 10.3389/fncel.2013.00250
Source DB: PubMed Journal: Front Cell Neurosci ISSN: 1662-5102 Impact factor: 5.505
Figure 1Homology model of the closed state of the human P2X2/3R. (A) A side view of the heterotrimeric hP2X2(3)2R in which both heteromeric interfaces are visible is shown in the middle. The P2X2 subunit is colored in cyan and the two P2X3 subunits are colored in orange and pink. Selected basic residues important for ATP binding are shown as spheres within the two intersubunit ATP-binding sites. For clarity, the same residues are shown as sticks in a close-up view with depiction of the distances between their side chains. (B) Frontal close-up views of the two heteromeric ATP-binding sites with a partial transparent surface to indicate the orientation of the residues. The coloring of the subunits is the same as in (A). Differences in the three-dimensional structures and volumes of the hydrophilic cavities are clearly seen. (C) Surface representations of the same view as in (B) with gradual depiction of hydrophobic (green) or hydrophilic (pink) areas/residues. Neutral areas are shown gradually white. The hP2X2/3R homology model was generated and visualized by the molecular modeling program MOE2012.10 (Molecular Operating Environment 2012, CCG, Montreal, Canada) using the apo zP2X4 crystal structure (PDB entry 3H9V; (Kawate et al., 2009) as a template as previously described (Wolf et al., 2011; Hausmann et al., 2013).
Summary of the distribution of P2XR subunits in selected mammalian cell types.
| T-cells: Jurkat cell line( | (+) | + | + | (+) | + | + | + | Ca2+ imaging, siRNA: P2X1, P2X4, P2X7 | |||||||
| T-cells: human primary CD4+( | (+) | + | + | + | + | + | Pharmacological inhibition, Ca2+ imaging: P2X1, P2X4 | ||||||||
| Mast cells: LAD2 and human lung mast cells( | + | + | (+) | + | Patch clamp: P2X1, P2X4, P2X7 | ||||||||||
| Freshly isolated mouse peritoneal macrophages([ | (+) | + | + | + | + | KO mouse: P2X1, P2X4 | |||||||||
| J774 cells( | + | + | (+) | + | + | + | + | + | Ca2+ imaging, patch clamp: P2X4, P2X7 | ||||||
| Mouse spleen macrophages( | + | + | + | + | + | (+) | (+) | + | + | + | + | + | |||
| Human B lymphocytes([ | + | + | + | + | + | + | + | ||||||||
| HeLa cells( | (+) | + | + | + | + | + | Ca2+ imaging, changes in ATP-induced apoptosis: P2X7 | ||||||||
| Myocytes from renal artery( | + | + | Patch clamp: P2X1, P2X1/4 | ||||||||||||
| Endothelial cells([ | + | + | (+) | + | + | + | Ca2+ imaging: P2X4; KO mouse: P2X4, P2X1; patch-clamp: P2X7 | ||||||||
| Dorsal root ganglia (DRG) neurons([ | + | + | + | + | + | + | Patch clamp: P2X3, P2X2/3; KO mouse: P2X3, P2X2, P2X2/3 | ||||||||
| Nodose ganglia neurons([ | + | + | + | + | + | Patch clamp, KO mouse: P2X2, P2X2/3 | |||||||||
| Superior cervical ganglion (SCG) neurons([ | (+) | + | + | + | + | + | (+) | + | + | (+) | + | + | Patch clamp, Ca2+ imaging: predominantly P2X2; KO mouse: P2X1 | ||
| Urinary bladder afferent neurons([ | + | + | Bladder function, patch clamp: P2X3, P2X2/3; KO mouse: P2X2, P2X3, P2X2/3 | ||||||||||||
| P19 cells([ | Ca2+ imaging: P2X2, P2X2/6, P2X4; RNAi: P2X2, P2X7 | ||||||||||||||
| Undifferentiated | (+) | + | + | + | (+) | (+) | (+) | (+) | + | (+) | |||||
| Differentiated to progenitors | (+) | + | (+) | (+) | + | + | + | (+) | + | (+) | (+) | + | (+) | ||
| Neuronally differentiated neural progenitors( | + | (+) | (+) | (+) | + | ||||||||||
| Astrocytes([ | + | (+) | + | + | + | + | + | + | + | + | + | + | + | Patch clamp: P2X1/5; YO-PRO uptake, RNAi: P2X7 | |
| Microglia([ | Nerve injury, KO mouse: P2X4; patch clamp: P2X4, P2X7; YO-PRO uptake: P2X7 | ||||||||||||||
| Freshly isolated | (+) | + | + | ||||||||||||
| Primary culture | + | + | |||||||||||||
| BV-2 cells | + | + | + | + | |||||||||||
| C8-B4 cells | (+) | + | + | + | + | ||||||||||
| Oligodendrocytes( | + | Ca2+ imaging: P2X7 | |||||||||||||
| Oligodendrocytes (progenitors)( | + | + | + | + | + | Ca2+ imaging, patch clamp: P2X7 | |||||||||
| Human salivary gland epithelial (HSG) cells( | + | + | + | + | + | + | |||||||||
| Human embryonic kidney (Hek) 293 cells( | |||||||||||||||
| Normal conditions | (+) | (+) | |||||||||||||
| Grown past confluence | + | + | + | + | + | ||||||||||
| Vascular smooth muscle cells([ | + | + | + | + | + | + | + | + | Patch clamp: P2X1 | ||||||
| Non-cystic fibrosis epithelial cells (16HBE14o−)( | + | + | + | ||||||||||||
| Cystic fibrosis cells (IB3-1)( | + | + | + | + | + | + | RNAi, Ca2+ imaging: P2X4, P2X6 | ||||||||
| Adrenal gland pheochromocytoma (PC12) cells([ | Patch clamp, Ca2+ imaging: P2X2 | ||||||||||||||
| Undifferentiated | + | + | |||||||||||||
| NGF-differentiated | + | + | + | + | + | + | + | + | + | + | + | + | + | + | |
Except primates,
except septal vessels,
except cerebral vessels.
References in table:
Woehrle et al., 2010a;
Wareham et al., 2009;
Sim et al., 2007;
Ulmann et al., 2010;
Coutinho-Silva et al., 2005;
Sluyter et al., 2001;
Wang et al., 2004;
Welter-Stahl et al., 2009;
Harhun et al., 2010;
Yamamoto et al., 2000;
Harrington et al., 2007;
Wilson et al., 2007;
Lewis et al., 1995;
Cockayne et al., 2000;
Cockayne et al., 2005;
Compan et al., 2012;
Serrano et al., 2012;
Xiang et al., 1998,
Calvert and Evans, 2004;
Vlaskovska et al., 2001;
Zhong et al., 2001;
Zhong et al., 2003;
Da Silva et al., 2007;
Resende et al., 2007;
Resende et al., 2008;
Yuahasi et al., 2012;
Schwindt et al., 2011;
Franke et al., 2001;
Kukley et al., 2001;
Lalo et al., 2008;
Yamamoto et al., 2013;
Tsuda et al., 2003;
Qureshi et al., 2007,
Raouf et al., 2007;
Ulmann et al., 2008;
Toulme et al., 2010;
Agresti et al., 2005;
Matute et al., 2007;
Worthington et al., 1999;
Nori et al., 1998;
Lewis and Evans, 2000;
Lewis and Evans, 2001;
Liang et al., 2005;
Michel et al., 1996;
Sun et al., 2007;
Hickman et al., 2013.